CNSP stock touches 52-week low at $2.2 amid sharp annual decline

CNS Pharmaceuticals Inc (NASDAQ:CNSP) stock has reached a new 52-week low, trading at $2.2, as the company faces a staggering 1-year change with a decline of -99.75%. According to InvestingPro data, the company’s market capitalization has shrunk to just $2.64 million, with the stock showing continued weakness across multiple timeframes, including a -15.62% decline in the past week alone. This significant drop reflects a challenging period for the pharmaceutical company, which has seen its market value erode almost entirely over the past year. While the company maintains more cash than debt on its balance sheet, InvestingPro analysis indicates rapid cash burn and weak gross profit margins. Investors are closely monitoring CNSP’s performance and potential turnaround strategies as the stock grapples with this low price level, with analyst price targets ranging from $25 to $200, suggesting potential upside despite current challenges. InvestingPro subscribers have access to 13 additional key insights about CNSP’s financial health and prospects.

In other recent news, CNS Pharmaceuticals has announced that its current cash reserves are projected to sustain operations until the first quarter of 2026. The company also confirmed maintaining its NASDAQ Capital Market listing. CNS Pharmaceuticals recently enacted a 1-for-50 reverse stock split to comply with Nasdaq’s minimum bid price requirement, which was approved by shareholders during a special meeting. This reverse split, effective February 21, 2025, aims to increase the share price while keeping the overall value of shares substantially the same. Additionally, shareholders approved the repricing of certain warrants, setting the new exercise price to the lower of $1.13 per share or the closing stock price on the approval date. The company is on track to release primary data analysis from its global clinical trial for Berubicin, its leading drug candidate, in the first half of 2025. CNS Pharmaceuticals plans to initiate the clinical program for its second drug candidate, TPI 287, by the end of the year. These developments highlight CNS Pharmaceuticals’ strategic focus on financial management and drug development progress.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.